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BACKGROUND & AIMS: Some patients develop multiple
squamous cell carcinomas (SCCs) in the upper aerodigestive
tract, attributed to ﬁeld cancerization; alcohol consumption has
been associated with this process. We examined the association
between multiple areas of dysplastic squamous epithelium with
the development of SCC of the esophagus or head and neck
cancer, as well as alcohol consumption and smoking.
METHODS: We examined 331 patients with early stage
esophageal SCC using Lugol chromoendoscopy to evaluate the
dysplastic squamous epithelium in the esophagus. Patients then
were assigned to 3 groups, based on the number of Lugol-
voiding lesions: A, no lesion; B, 1–9 lesions; or C, 10 or more
lesions. Participants completed lifestyle surveys on their his-
tory of drinking, smoking, and diet. All participants were
evaluated by laryngopharyngoscopy before registration; only
those without head and neck cancer were included, except for
patients with superﬁcial SCC limited to the subepithelial layer.
Lesions detected in the esophagus and head and neck by sur-
veillance were considered to be metachronous. The study endpoint was the cumulative incidence of metachronous SCCs in
the esophagus and head and neck after endoscopic resection of
esophageal SCC, according to the grade of Lugol-voiding lesions.
At study entry, all patients were instructed to abstain from
alcohol and smoking. RESULTS: Over the 2-year study period,
metachronous SCCs of the esophagus were detected in 4% of
patients in group A, in 9.4% of patients in group B, and in
24.7% of patients in group C (P < .0001 for patients in group A
vs B or B vs C). Head and neck SCCs were detected in none of
the patients in group A, in 1.7% of the patients in group B, and
in 8.6% of the patients in group C (P ¼ .016 for patients in
group A vs C and P ¼ .008 for patients in group B vs C). SCC of
the esophagus or head and neck developed in 4.0% of patients
in group A, in 10.0% of patients in group B, and in 31.4% of
patients in group C (P < .0001 for group A vs B or A vs C).
Alcohol abstinence decreased the risk of multiple SCCs of the
esophagus (adjusted hazard ratio, 0.47, 95% conﬁdence inter-
val, 0.25–0.91; P ¼ .025), whereas smoking abstinence did not.
CONCLUSIONS: Multiple dysplastic lesions in the esophagus
increase the risk of multiple SCCs. Alcohol abstinence reduces
the risk of metachronous SCCs. Clinical Trials registry:
UMIN000001676 and UMIN000005466.
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ATSsquamous cell carcinoma (SCC) in the upper aero-
digestive tract including the esophagus and the head
and neck region has been referred to as the phenomenon
of “ﬁeld cancerization”1 and adversely affects patient sur-
vival.2 Recent endoscopic imaging technology such as
narrow-band imaging can detect early SCC, and minimally
invasive endoscopic treatment can achieve cure and
organ preservation.3–6 Conversely, cancer survivors after
curative treatment are at risk for the development of
metachronous multiple SCCs in the preserved organ.
However, little is known about the interval from the ﬁrst
SCC to the metachronous SCC and the risk of metachronous
SCC.
Squamous dysplasia has been believed to be a preneo-
plastic lesion of SCC, and it is identiﬁed easily as Lugol-
voiding lesions (LVL) on Lugol chromoendoscopy.7,8 Some
patients with esophageal SCCs have multiple LVLs in the
background esophageal mucosa.9–13 However, prospective
data on the association between the grade of LVL and the
risk of metachronous SCC are lacking. In addition, mutation
of the TP53 gene in the background esophageal mucosa was
shown as an early event of esophageal carcinogenesis.
Moreover, TP53 gene mutations were detected even in the
microscopically normal epithelium.14 However, data on the
association between the grade of LVL and TP53 status also
are lacking. Follow-up data on LVL might provide important
information about the risk of metachronous SCC.
Although ﬁeld cancerization is associated closely with
alcohol consumption and insufﬁcient alcohol meta-
bolism,15,16 the beneﬁt of alcohol abstinence on the ﬁeld
cancerization phenomenon remains unclear. In this study,
we evaluated the cumulative incidence of metachronous
multiple SCCs in the esophagus and the head and neck
region according to the grade of LVL, as well as the risk
factors of metachronous multiple SCCs and the effect of
alcohol and smoking abstinence on ﬁeld cancerization.Abbreviations used in this paper: ALDH2, aldehyde dehydrogenase-2; CI,
conﬁdence interval; EMR, endoscopic mucosal resection; ESD, endo-
scopic submucosal dissection; LVL, Lugol voiding lesion; RR, relative risk;
SCC, squamous cell carcinoma.
Most current article
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Study Design
From September 2005 through May 2010, we prospectively
recruited patients from 16 hospitals throughout Japan. This
cohort study was approved by the institutional review board
at each hospital, and we obtained written informed consent
from all patients (UMIN Clinical Trials Registry ID:
UMIN000001676). The genetic analysis also was approved
by the Institutional Review Board of Kyoto University Hospital,
and all participants provided written informed consent (UMIN
Clinical Trials Registry ID: UMIN000005466).
Study Population
Inclusion criteria of this cohort study were as follows: (1)
newly diagnosed early SCC of the esophagus; (2) completeendoscopic resection by endoscopic mucosal resection (EMR)
or endoscopic submucosal dissection (ESD); (3) tumor-negative
vertical margins of resected specimens; (4) tumor invasion
limited to the mucosa on histopathologic examination of
resected specimens; (5) no additional treatment (surgical
resection, radiotherapy, chemotherapy, and so forth) immedi-
ately after EMR or ESD; (6) no active head and neck cancer; (7)
patients were evaluated by their attending physicians to be in
good general condition, allowing at least 2 years of follow-up
evaluation; and (8) written informed consent obtained from
the patient. Exclusion criteria were as follows: (1) a history of
chemotherapy for any other cancer or a history of surgical
treatment or radiotherapy for head and neck cancer; (2) a
history of iodine allergy; and (3) patients whom the investi-
gator considered unsuitable as subjects.
We also prospectively examined TP53 mutations in the
background esophageal mucosa in other patients with early
esophageal SCC who were treated at Kyoto University Hospital.
Grading of LVL
LVL was graded according to the number of LVLs per
endoscopic view (A, no lesions; B, 1–9 lesions; C, 10 lesions)
(Figure 1). Endoscopic images obtained from eligible patients at
study entry were reviewed centrally in a blinded fashion by 3
endoscopists to determine the grade of LVL.
Survey of Lifestyle and Flushing
Reaction After Drinking
At study entry, lifestyle surveys were conducted using a
self-administered questionnaire (Supplementary Figure 1). The
histories of drinking, smoking, and consumption of high-
temperature foods, green-yellow vegetables, and fruit were
documented carefully. The same questionnaire was used to
obtain detailed information on each subject. Patient reports of
facial ﬂushing after drinking alcohol were presumed to be
markers of insufﬁcient alcohol metabolism owing to inactive
aldehyde dehydrogenase-2 (ALDH2) genotype (present and
past ﬂushing were indicative of inactive ALDH2 and never
ﬂushing was indicative of active ALDH2).17
Deﬁnition of Synchronous and
Metachronous Cancer
All candidates were surveyed by laryngoscopy by an
otolaryngologist to conﬁrm whether they had synchronous
multiple cancers in the head and neck region before registra-
tion. The surveillance interval was within 6 months. Only
patients without active head and neck cancer were eligible,
except for patients with superﬁcial SCCs limited to within the
Figure 1.Grading of LVLs. The number of LVLs per endoscopic view was counted, and the grading was divided into the
following 3 categories: (Group A) grade A, no lesions; (Group B) grade B, 1-9 lesions; and (Group C) grade C, 10 or more
lesions.
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registration and lesions including the esophagus were deﬁned
as synchronous lesions. After registration, all of the patients
were followed up by a planned schedule according to the
protocol. If a new lesion was detected at the ﬁrst follow-up
evaluation (3 months after registration) or thereafter, such a
lesion was deﬁned as a metachronous lesion.
Follow-Up Examinations
Endoscopic examinations of the head and neck, esoph-
agus, and stomach, as well as Lugol chromoendoscopy, were
performed at 3-month intervals for up to 6 months after EMR
or ESD. Subsequently, these examinations were repeated
every 6 months. The head and neck region was examined by
laryngoscopy by an otolaryngologist at the time of EMR or
ESD and at 1-year intervals thereafter.18 In addition to oto-
laryngologists, gastrointestinal endoscopists also examined
the oropharynx and hypopharynx during surveillance
endoscopy.
Alcohol and Smoking Abstinence
At study entry, the physicians in charge handed a document
describing the importance of alcohol and smoking abstinence to
all patients and verbally instructed them to stop drinking and
smoking. At each examination, we surveyed smoking status
(nonsmoker or smoker; for smokers, the number of cigarettes
smoked per day) and drinking status (nondrinker or drinker;
for drinkers, the drinking frequency and amount of alcohol
consumed) by self-reporting and instructed patients not to
drink or smoke.
Histologic Analysis
Although the diagnosis of invasive SCC did not usually differ
among the pathologists, the diagnosis of high-grade intra-
epithelial neoplasia sometimes was discordant. To control these
differences, lesions with a diagnosis of high-grade intra-
epithelial neoplasia were reviewed centrally in a blinded
fashion by 3 pathologists. Lesions present at enrollment as well
as new lesions were examined. Lesions not diagnosed to behigh-grade intraepithelial neoplasia or SCCs on central review
were excluded from this analysis.
TP53 Mutation in Background
Esophageal Mucosa
Biopsy specimens were taken from noncancerous back-
ground esophageal mucosa. Genomic DNA was extracted using
the Gentra Puregene Tissue Kit protocol (Qiagen, Inc, Hilden,
Germany) with several modiﬁcations, and a low frequency of
TP53 mutations was detected by deep sequencing of the ampli-
cons by using the TruSeq Amplicon Cancer Panel (Illumina, Inc,
San Diego, CA) to sequence mutational hotspots. This cancer
panel includes hotspots of TP53mutation, but not all TP53 exons.
The amplicon libraries were subjected to massively parallel
sequencing using MiSeq (Illumina, Inc) with 170-bp paired-end
reads. The sequencing data were imported to the CLC Geno-
mics Workbench software (version 6.0.1; CLC bio, Aarhus,
Denmark), and low-quality data were trimmed by a quality limit
of 0.001. The cleaned-up reads were mapped to the human
genome (GRCh37_dbSNP135), and the somatic mutations were
detected by the Quality-based Variant Detection command.
Statistical Analysis
We examined whether the grade of LVL was associated with
the development of metachronous multiple SCCs in the
esophagus and head and neck region. The number of patients
required to detect a difference between grades A and B with a
statistical power of 80% and a signiﬁcance level of 5% was
estimated assuming that the cumulative rate of metachronous
SCCs in grades A, B, and C, would be 1%, 10%, and 30%,
respectively, with a patient ratio of 4:4:2 and a drop-out rate of
10%. The total number of patients required was estimated to
be 292. Under these conditions, the statistical power to detect a
difference between grades A and C would be 99% or greater
(signiﬁcance level, 5%). The planned number of enrolled
patients was set at 330, taking into account drop-outs and
ineligible patients.
The Kaplan–Meier method and the log-rank test were
performed for the analysis of development of a second pri-
mary SCC in the esophagus and the head and neck region. We
Figure 2. Enrollment and
subjects for analysis.
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treatment to the day of endoscopic diagnosis of a second
primary SCC. The person-year method was used to calculate
the total number of multiple cancers arising in the esophagus
and head and neck per 100 person-years (ie, a patient could
have multiple events); the Poisson regression analysis was
used to estimate the sex- and age-adjusted relative risk (RR)
of all arising events. A Cox proportional-hazards model was
used to estimate the sex- and age-adjusted hazard ratio (RR)
and 95% conﬁdence interval (CI) of the primary event. The
analysis of end points was conducted after the completion of
at least 2 years of follow-up observation for all patients from
the time of enrollment. Data on patients in whom follow-up
examinations were not completed were censored at the last
observation. All data were analyzed with SAS (version 9; SAS
Institute, Inc, Cary, NC). All authors had access to the study
data and reviewed and approved the ﬁnal manuscript.Results
Study Population
A total of 332 patients with early esophageal SCC were
enrolled. One patient refused to participate in this cohort
study. The other 331 patients were registered and under-
went the preplanned follow-up examinations. One patient
was excluded because the lesion was not diagnosed deﬁni-
tively as high-grade intraepithelial neoplasia or invasive SCCon central review of the pathologic assessment (Figure 2).
Table 1 summarizes the baseline characteristics of the
330 patients according to the grade of LVL. The median
follow-up period was 49.4 months (range, 1.3–81.2 mo). The
proportion of men was higher in the more severe LVL
grades (62.0%, 85.1%, and 93.4%, respectively; P < .0001
for A or B vs C). The largest subgroup according to age was
60 to 69 years in grade C and 70 years or older in grades A
and B. After adjusting for sex and age, the LVL grade was
associated with progressively higher proportions of heavy
drinkers (27.7%, 26.2%, and 52.8%, respectively; P < .0001
for trend, vs others), heavy smokers (41.1%, 65.9%, and
71.0%, respectively; P < .0001 for trend), not eating green-
yellow vegetables almost every day (52.0%, 54.9%, and
71.3%, respectively; P ¼ .021 for trend), and patients with a
low body mass index (23.4%, 32.0%, and 37.4%, respec-
tively; P ¼ .027 for trend).Primary and Secondary Outcomes
LVL grade was associated with progressive increases in
the 2-year cumulative incidence of metachronous multiple
SCCs (esophagus: 4.0%, 9.4%, and 24.7%, respectively;
P < .0001 for A or B vs C; head and neck region: 0.0%, 1.7%,
and 8.6%, respectively; P ¼ .016 for A vs C and P ¼ .008 for
B vs C; both: 4.0%, 10.0%, and 31.4%, respectively; P <
.0001 for A or B vs C) (Figure 3).
Table 1.Clinical Characteristics of Patients According to the LVL Grade
LVL grade
A (n ¼ 50) B (n ¼ 174) C (n ¼ 106) P
Sex
Male, % 62.0% 85.1% 93.4% <.0001
Age, y
40–59 22.0% 17.2% 19.8%
60–69 36.0% 36.8% 55.7%
70 42.0% 46.0% 24.5% .005 a
Means ± SD 66.4 ± 9.9 67.7 ± 8.6 64.8 ± 6.5 .018 a
Sex- and age-adjusted % or mean
Drinking alcoholb,c
Never/rare 25.9% 7.9% 4.7%
Light 13.8% 21.4% 8.9%
Moderate 27.8% 30.9% 25.5%
Heavyd 27.7% 26.2% 52.8%
Ex-drinker 4.7% 13.6% 8.2% <.0001 a
Means ± SEe 10.4 ± 1.8 13.1 ± 0.9 19.9 ± 1.2 <.0001 f
Strong alcoholic beveragesb
Frequently 6.7% 11.8% 12.2%
Sometimes 15.1% 20.1% 23.2%
Never 78.2% 68.1% 64.6% .17 f
Smoking, pack-yearsb
Never, 0 22.7% 14.8% 12.4%
Light, <30 36.2% 19.3% 16.6%
Heavy, 30 41.1% 65.9% 71.0% <.0001 f
High-temperature foodb
Likes very much 18.4% 20.8% 20.6%
Likes somewhat 24.5% 25.1% 24.0%
Neither likes nor dislikes 45.8% 41.8% 36.8%
Dislikes somewhat 9.3% 9.9% 15.9%
Dislikes very much 2.0% 2.3% 2.7% .81 f
Green-yellow vegetablesb
Seldom 0.0% 3.8% 2.1%
1–2 d/mo 3.8% 5.7% 5.5%
1–2 d/wk 20.5% 16.5% 35.3%
3–4 d/wk 27.7% 29.0% 28.4%
Almost every day 48.0% 45.1% 28.7% .021 f
Fruitb
Seldom 11.1% 9.6% 12.8%
1–2 d/mo 5.2% 15.2% 12.6%
1–2 d/wk 33.4% 22.9% 33.1%
3–4 d/wk 26.2% 20.2% 17.0%
Almost every day 24.1% 32.0% 24.5% .31 f
Body mass index, kg/m2g
<21.2 23.4% 32.0% 37.4%
21.2–23.6 18.8% 37.1% 33.9%
23.7 57.8% 30.9% 28.7% .003 f
Means ± SE 23.5 ± 0.44 22.3 ± 0.24 22.1 ± 0.31 .027 f
Alcohol ﬂushingb
Never ﬂushing 35.2% 31.5% 40.6%
Flushingh 64.8% 68.5% 59.4% .12 a
aP for trend across the 3 groups.
bPercentage values were adjusted for sex and age by direct method (using all patients as the standard population) and
statistically tested by the Cochran–Mantel–Haenszel test. Mean values were adjusted for sex and age and were statistically
tested by analysis of covariance.
cNever/rare, <1 U/wk; light, 1–8.9 U/wk; moderate, 9–17.9 U/wk; heavy, 18 U/wk (1 U ¼ 22 g ethanol).
dP < .0001 for trend, vs others.
eExcluding ex-drinkers.
fP for homogeneity among the 3 groups.
gCategorized by the overall tertile. Missing data for 1 patient.
hPresent or past ﬂushing.
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Figure 3. Cumulative incidence of metachronous multiple SCCs according to the LVL grade: (A) esophagus, (B) head and neck
region, and (C) esophagus and head and neck region.
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the total number of metachronous multiple SCCs per 100
person-years (esophagus: RR, 1.91 and 7.41 for grades B and
C, respectively, vs grade A; P < .0001 for trend; head and
neck region: RR, 0.00 and 5.74 for grades A and C, respec-
tively, vs grade B; P < .0001 for trend; both: RR, 2.19 and
9.05 for grades B and C, respectively, vs grade A; P < .0001
for trend) (Table 2). The frequency of events was notably
high in grade C (18.9, 5.8, and 24.7 per 100 person-years in
esophagus, head and neck region, and both, respectively).
Grade C LVL was the most signiﬁcant predictor of
metachronous multiple SCCs on analysis with a univariate
or multivariate Cox proportional-hazards model (esoph-
agus: multivariate RR, 8.76; 95% CI, 3.02–25.5; for C vs. A;
head and neck region: multivariate RR, 3.51; 95% CI,
1.34–9.20; for C vs B; both: multivariate RR, 9.78; 95% CI,
3.41–28.0; for C vs A) (Table 3). On multivariate analysis, an
alcohol ﬂushing reaction after drinking was also a predictor
of metachronous esophageal SCC (RR, 1.07; 95% CI,
1.02–2.82) and esophageal and head and neck SCC (RR,
1.60; 95% CI, 1.00–2.57). Small or large body mass index
also was associated with metachronous esophageal SCC (RR,
2.09; 95% CI, 1.14–3.83; and RR, 1.86; 95% CI, 1.00–3.47,
respectively) and esophageal and head and neck SCC (RR,
1.73; 95% CI, 0.99–3.02; and RR, 1.55; 95% CI, 0.88–2.73,
respectively).TP53 Gene Alteration in Background
Esophageal Mucosa
To examine whether mutations of genes such as TP53
occurred in the noncancerous esophageal mucosa with
multiple LVLs and whether the mutation frequency was
associated with the severity of LVLs, we performed deep
sequencing of the TP53 gene amplicon using biopsy speci-
mens of noncancerous esophageal mucosa in patients with
or without multiple LVLs. These samples were obtained
from 38 early esophageal SCC cases independent from our
present cohort study. The clinical characteristics are sum-
marized in Supplementary Tables 1 and 2, and the detected
low frequency of TP53 mutations (2% of total reads) are
listed in Supplementary Table 3. Our study showed that the
number of cases that had a TP53 mutation was 3 of 7(42.9%) in grade A, 5 of 9 (55.6%) in grade B, and 17 of 22
(77.3%) in grade C (Supplementary Figure 2). Of note,
several mutations (2–6 mutations) of the TP53 gene were
found simultaneously in biopsy specimens of noncancerous
esophageal mucosa in patients with grade C LVL
(Supplementary Figure 2). The median mutation frequency
of TP53 genes in biopsy specimens was 0%, 2.0%, and
10.1% in grades A, B, and C, respectively. The median in
grade C was signiﬁcantly higher than that in grade A
(P ¼ .04) (Supplementary Figure 3).Effect of Alcohol and Smoking Abstinence on the
Development of Metachronous SCC
As shown in Supplementary Figure 4, 69 (30.9%) of 223
patients who drank 1 U/day (22 g of ethanol) or more at
baseline abstained from drinking alcohol, and 69 (53.5%) of
129 patients who had smoked at baseline abstained from
smoking. The cumulative incidence of metachronous multi-
ple SCCs in the esophagus was shown according to the
status of drinking alcohol and smoking (Figure 4). Hazard
ratios were adjusted for sex, age, LVL grade, alcohol intake
at baseline, and alcohol ﬂushing.
Alcohol abstinence decreased the risk of developing
metachronous multiple SCCs of the esophagus (adjusted
hazard ratio, 0.47; 95% CI, 0.25–0.91; P ¼ .025) (Figure 4A).
The risk reduction was especially large in grade C LVL
(adjusted hazard ratio, 0.23; 95% CI, 0.09–0.60; P ¼ .003)
(Figure 4B). In contrast, smoking abstinence did not
decrease the risk of developing metachronous multiple SCCs
of the esophagus (all: adjusted hazard ratio, 0.59; 95% CI,
0.29–1.18; P ¼ .13; grade C LVL: adjusted hazard ratio, 0.73;
95% CI, 0.32–1.67; P ¼ .45) (Figure 4C and D, respectively).Discussion
We found that patients with grade C LVL were at sig-
niﬁcant risk for the development of metachronous multiple
SCCs in the esophagus and the head and neck region.
Furthermore, TP53 mutation in the background esophageal
mucosa was associated with an increased grade of LVL.
These results clearly supported the theory of ﬁeld cancer-
ization in which genetic alteration in the background
Table 2.Person-Years and Number of Primary and All Events According to the Grade of LVL
LVL grade
Total (n ¼ 330)A (n ¼ 50) B (n ¼ 174) C (n ¼ 106)
Esophagus
Primary events
Events, n 4 26 44 74
Person-years 208.1 652.0 327.1 1187.2
Per 100 person-years 1.9 4.0 13.5 6.2
RRa 1 2.32 7.68 P < .0001
95% CI Referent 0.79–6.82 2.64–22.3 for trend
All events
Events, n 6 33 85 124
Person-years 215.6 703.2 449.9 1368.6
Per 100 person-years 2.8 4.7 18.9 9.1
RRb 1 1.91 7.41 P < .0001
95% CI Referent 0.78–4.69 3.12–17.6 for trend
Head and neck
Primary events
Events, n 0 6 14 20
Person-years 215.6 687.0 407.9 1310.4
Per 100 person-years 0.0 0.9 4.1 1.5
RRa 0.00 1 3.64 P ¼ .002
95% CI Incalculable Referent 1.39–9.52 for trend
All events
Events, n 0 7 26 33
Person-years 215.6 703.2 449.9 1368.6
Per 100 person-years 0.0 1.0 5.8 2.4
RRb 0.00 1 5.74 P < .0001
95% CI Incalculable Referent 0.08–0.40 for trend
Esophagus, head and neck
Primary eventsc
Events, n 4 29 50 83
Person-years 208.1 640.0 306.0 1154.1
Per 100 person-years 1.9 4.5 16.3 7.2
RRa 1 2.48 8.52 P < .0001
95% CI Referent 0.85–7.19 2.97–24.4 for trend
All eventsd
Events, n 6 40 111 157
Person-years 215.6 703.2 449.9 1368.6
Per 100 person-years 2.8 5.7 24.7 11.5
RRb 1 2.19 9.05 P < .0001
95% CI Referent 0.91–5.26 3.87–21.2 for trend
aSex- and age-adjusted hazard ratio by Cox proportional-hazards model.
bSex- and age-adjusted relative risk by Poisson regression.
cEsophagus or head and neck cancer.
dEsophagus plus head and neck cancer(s).
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the potential to develop metachronous multiple SCCs. In
addition, alcohol abstinence signiﬁcantly decreased the
development of metachronous SCCs, especially in the pa-
tients with grade C LVL. This result indicates that alcohol
abstinence should be encouraged to reduce the risk of
metachronous multiple SCCs after curative treatment.
Although the ﬁeld cancerization phenomenon in the
upper aerodigestive tract has been well known for more
than half a century, it has been difﬁcult to detect early
cancer in this region. A randomized controlled trial found
that narrow-band imaging effectively can detect early SCC in
the esophagus and the head and neck region.3 In patientswith early SCC, organs can be preserved by endoscopic
curative treatment, but the preserved organs are affected
strongly by the ﬁeld cancerization phenomenon. Therefore,
an effective surveillance strategy after treatment and
methods to prevent metachronous multiple SCCs are needed
in survivors of esophageal SCC.
Data on the interval from the ﬁrst SCC to the develop-
ment of a second primary metachronous SCC have been
limited, largely because of dismal survival, complete
esophageal resection on diagnosis, poor follow-up evalua-
tion, and lack of effective surveillance programs. In this
study, we focused on patients with early esophageal SCC
who could achieve cure and organ preservation. The
Table 3.Predictors of Metachronous Multiple Cancers by Cox Proportional-Hazards Model
Esophagus Head and neck Esophagus or head and neck
Univariate
RR (95% CI)a
Multivariate
RR (95% CI)b
Univariate RR
(95% CI)a
Multivariate
RR (95% CI)b
Univariate
RR (95% CI)a
Multivariate
RR (95% CI)b
Grade of LVLs
A 1 (ref) 1 (ref) 0.00 (incalculable) 0.00 (incalculable) 1 (ref) 1 (ref)
B 2.33 (0.79–6.85) 2.46 (0.84–7.24) 1 (ref) 1 (ref) 2.49 (0.86–7.23) 2.64 (0.91–7.68)
C 7.66 (2.64–22.3) 8.76 (3.02–25.5) 3.61 (1.38–9.46) 3.51 (1.34–9.20) 8.51 (2.97–24.4) 9.78 (3.41–28.0)
Drinking alcohol, per þ1 U 1.12 (1.02–1.23) – 1.18 (1.01–1.38) – 1.11 (1.01–1.22) –
Alcohol ﬂushing
Never ﬂushing 1 (ref) 1 (ref) 1 (ref) – 1 (ref) 1 (ref)
Flushing 1.39 (0.84–2.29) 1.70 (1.02–2.82) 1.29 (0.49–3.37) – 1.30 (0.82–2.07) 1.60 (1.00–2.57)
Strong alcoholic beverages
Sometimes/never 1 (ref) – 1 (ref–) – 1 (ref) –
Frequently 0.95 (0.45–1.99) – 1.17 (0.34–4.05) – 1.07 (0.55–2.08) –
Smoking, pack-years
Never/light (<30) 1 (ref) – 1 (ref) – 1 (ref) –
Heavy (30) 1.12 (0.66–1.92) – 1.80 (0.57–5.66) – 1.15 (0.69–1.91) –
High-temperature food
Likes very much 1.04 (0.57–1.90) – 0.93 (0.27–3.20) – 1.09 (0.62–1.92) –
Others 1 (ref) – 1 (ref) – 1 (ref) –
Green-yellow vegetables
Almost every day 0.77 (0.46–1.26) – 0.59 (0.21–1.68) – 0.64 (0.39–1.03) –
Others 1 (ref) – 1 (ref) – 1 (ref) –
Fruit
Almost every day 0.46 (0.24–0.87) 0.42 (0.22–0.82) 0.32 (0.07–1.45) 0.32 (0.07–1.43) 0.43 (0.23–0.81) 0.39 (0.21–0.74)
Others 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Body mass index, kg/m2
<21.2 2.06 (1.13–3.75) 2.09 (1.14–3.83) 1.29 (0.46–3.60) – 1.65 (0.95–2.85) 1.73 (0.99–3.02)
21.2–23.6 1 (ref) 1 (ref) 1 (ref) – 1 (ref) 1 (ref)
23.7 1.59 (0.86–2.94) 1.86 (1.00–3.47) 0.67 (0.21–2.13) – 1.33 (0.76–2.33) 1.55 (0.88–2.73)
NOTE. One patient with missing data for body mass index was excluded (n ¼ 329).
–, Not selected (P  .15). Sex and age also were adjusted but are not shown in the table.
aSex- and age-adjusted RR for each variable.
bVariables were selected from all the variables listed above by the stepwise procedure with P < .15 for entry and removal, and
the relative risks were shown for the selected variables.
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ATfrequency of events was notably low in grade A. The 2-year
cumulative incidence of metachronous multiple SCCs and
the total number of metachronous multiple SCCs per 100
person-years were 4.0%/2.8, 0.0%/0.0, and 4.0%/2.8 in the
esophagus, head and neck region, and both, respectively. On
the other hand, the frequency of events was notably high in
grade C. The 2-year cumulative incidence of metachronous
multiple SCCs and the total number of metachronous mul-
tiple SCCs per 100 person-years were 24.7%/18.9, 8.6%/
5.8, and 31.4%/24.7 in the esophagus, head and neck
region, and both, respectively. These results indicated that
effective surveillance programs according to the grade of
LVL or effective adjuvant strategies according to the grade
of LVL are required to detect metachronous SCC earlier.
There has been no effective biomarker for the risk of the
ﬁeld cancerization phenomenon. In this study, we clearly
showed that an increase in the grade of LVL is associated
closely with the risk of metachronous SCC. In addition, grade
C LVL and a ﬂushing reaction after drinking alcohol are
predictors of metachronous multiple SCCs. We previously
reported that multiple LVLs in patients with SCC in the
esophagus and the head and neck region was associatedwith ALDH2 inactive genotype and metachronous SCC in the
esophagus and the head and neck region.13,19,20 These data
mean that cancer survivors with ﬂushing reaction after
drinking alcohol or multiple LVLs in the background mu-
cosa, or both, should be considered as having a higher risk
of ﬁeld cancerization.
A recent meta-analysis showed that the alcohol-related
risk of esophageal SCC is reversible after alcohol absti-
nence, and 16 years are required until all increased risk
disappears.21 In our study, with a median follow-up period
of only 49.4 months (range, 1.3–81.2 mo), the risk of
metachronous SCC signiﬁcantly decreased after alcohol
abstinence, especially among the patients with grade C LVL,
in whom the hazard ratio decreased to 0.23. These data are
very important for reducing the risk of metachronous SCC in
cancer survivors who have received curative treatment.
The median follow-up time in our study was 49.4
months, which might be too short to draw strong recom-
mendations about the value of surveillance intervals. How-
ever, even in this short period, the patients with grade C LVL
had a risk of metachronous multiple SCCs in the esophagus
and the head and neck region. This means that close
Figure 4. Cumulative inci-
dence of metachronous
multiple esophageal SCCs
according to the status of
drinking alcohol and
smoking. (A) All patients
according to the status of
drinking alcohol. (B) Pa-
tients with grade C LVL
according to the status of
drinking alcohol. (C) All
patients according to the
status of smoking. (D) Pa-
tients with grade C LVL
according to the status of
smoking.
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ATsurveillance may be required for the patients with esopha-
geal cancer who were treated successfully. Clinically, the
grade of LVL on iodine staining of the background mucosa
should be evaluated initially. If the grade suggests a risk of
cancer, narrow-band imaging should be performed as sur-
veillance for the early detection of cancer.
We showed that the TP53 mutation was seen even in
noncancerous lesions in patients with early esophageal
SCC, and the frequency of the TP53 mutation was associ-
ated with the severity of LVL grade. We believe these data
help explain the mechanisms of metachronous esophageal
carcinogenesis. In this study, we obtained biopsy samples
from Lugol-stained lesions, in which glycogen granules are
rich and structural atypia is not seen. Such mucosa was
assumed to be “non-cancerous” esophageal epithelium.22
However, we could not exclude the possibility that the
greater the number of LVL lesions present in the patient,
the more likely the possibility that biopsy specimens from
normal mucosa still contain cryptic dysplasia that would
not have been detected by Lugol staining alone. In addition,
we could not address the difference regarding TP53 mu-
tations between the primary lesion and the noncancerous
background esophageal mucosa because we did not obtainDNA samples from primary lesions. Moreover, we could
not assess whether the different TP53 mutations identiﬁed
in the same case were derived from monoclonal or poly-
clonal origin. These limitations should be clariﬁed further
in future studies.
In conclusion, the grade of LVL is a useful predictor of
the risk of metachronous multiple SCCs arising in the
esophagus and the head and neck region in survivors of
esophageal cancer. Alcohol abstinence is required to reduce
the risk of metachronous multiple SCCs in the esophagus.Supplementary Material
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Supplementary Figure 1. A self-administered questionnaire for lifestyle surveys.
Supplementary Figure 2. TP53 mutations in biopsy speci-
mens of noncancerous background esophageal mucosa.
Deep sequencing of the TP53 gene amplicon was performed
to detect small frequencies of mutations (2% of total reads).
A rectangle shows a biopsy specimen of each case. A red
plot shows a mutation of TP53, and the plot size conforms to
the mutation frequency. The 38 cases are divided according
to their LVL grade (grade A, 7 cases; grade B, 9 cases; and
grade C, 22 cases). ALDH2*1/*1 (ALDH2 wild-type homozy-
gotes), ALDH2*1/*2 (ALDH2 heterozygotes), and ALDH2*2/*2
(ALDH2 mutant homozygotes) are shown with blue rectan-
gles, red rectangles, and yellow rectangles, respectively.
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Supplementary Figure 3. Comparison of the TP53 mutation
frequency between LVL grades. A circle plot shows a sum-
mation of TP53 mutation frequency in each case. The box
height represents the interquartile range showing the lower
quartile (25th percentile values) and upper quartile (75th
percentile values) values. The line in the box represents the
median, and the whiskers represent the minimum and
maximum TP53 mutation frequencies. The P values were
calculated by the Wilcoxon signed-rank test.
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Supplementary Figure 4. Patient ﬂow chart of alcohol and smoking abstinence according to the LVL grade. *P ¼ .90, †P ¼
.61, and ‡P ¼ .98. (A) ¼ a, (B) ¼ j, (C) ¼ b, (D) ¼ k.
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Supplementary Table 1.Clinical Characteristics of 38 Esophageal SCC Patients Analyzed With TP53 Deep Sequencing
Sample ID LVL grade ALDH2 genotype Age, y Sex Alcohol drinkinga Smoking, pack-year
S1 A *1/*1 74 Female Never 35.25
S2 A *1/*2 60 Female Never 0
S3 A *1/*1 85 Female Light 0
S4 A *1/*1 57 Male Light 40
S5 A *1/*1 64 Male Light 40
S6 A *1/*2 68 Male Moderate 30
S7 A *1/*1 60 Male Moderate 40
S8 B *1/*1 67 Male Heavy 129
S9 B *1/*2 69 Male Moderate 60
S10 B *1/*2 75 Male Moderate 45
S11 B *1/*2 72 Male Moderate 2.5
S12 B *1/*1 55 Female Heavy 12.5
S13 B *1/*1 68 Male Moderate 45
S14 B *1/*1 64 Female Heavy 40
S15 B *1/*2 75 Male Moderate 87
S16 B *1/*1 72 Male Moderate 45
S17 C *1/*2 75 Male Heavy 5
S18 C *1/*2 71 Male Never 38
S19 C *1/*2 53 Male Heavy 70
S20 C *1/*1 62 Female Moderate 20
S21 C *1/*2 67 Male Heavy 70.5
S22 C *1/*2 61 Male Moderate 40
S23 C *1/*2 64 Male Moderate 34.5
S24 C *1/*2 71 Male Moderate 75
S25 C *2/*2 58 Male Heavy 40
S26 C *1/*2 61 Male Moderate 20
S27 C *1/*1 69 Male Heavy 21.5
S28 C *1/*1 59 Female Moderate 40
S29 C *1/*2 67 Male Moderate 100
S30 C *1/*2 59 Male Moderate 20
S31 C *1/*2 59 Male Heavy 0
S32 C *1/*2 73 Male Heavy 30
S33 C *1/*2 64 Male Heavy 39.6
S34 C *1/*2 68 Male Heavy 50
S35 C *1/*2 71 Male Heavy 75
S36 C *1/*2 69 Male Heavy 51
S37 C *1/*2 66 Male Heavy 86
S38 C *1/*2 50 Male Heavy 270
aNever/rare, <1 U/wk; light, 1–8.9 U/wk; moderate, 9–17.9 U/wk; heavy, 18 U/wk (1 U ¼ 22 g ethanol).
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Supplementary Table 2.Clinical Characteristics of 38
Esophageal SCC Patients
According to the LVL Grade
LVL grade
A (n ¼ 7) B (n ¼ 9) C (n ¼ 22)
Sex
Male, % 57.1% 77.8% 91.0%
Age, y
Means ± SD 67 ± 10 69 ± 6 64 ± 6
Drinking alcohola
Never/rare 28.6% 0.0% 4.5%
Light 42.9% 0.0% 0.0%
Moderate 28.6% 66.7% 36.4%
Heavy 0.0% 33.3% 59.1%
Heavy smoker, 30 pack-years 71.4% 77.8% 72.7%
ALDH2 genotype
*1/*1 71.4% 55.6% 13.6%
*1/*2 28.6% 44.4% 81.8%
*2/*2 0.0% 0.0% 4.5%
aNever/rare, <1 U/wk; light, 1–8.9 U/wk; moderate, 9–17.9
U/wk; heavy, 18 U/wk (1 U ¼ 22 g ethanol).
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Supplementary Table 3.Summary of TP53 Mutations in 38 Esophageal SCC Patients
Sample ID Mutation type Coverage Frequency Start position End position Reference allele Mutated allele Amino acid change Cosmic occurrence
S5 Nonsynonymous SNV 891 2.5 7578446 7578446 T A I162F 10
S6 Nonsynonymous SNV 1243 2.7 7578532 7578532 A C M133R 6
S6 Frameshift deletion 1030 2.0 7577572 7577572 T – 2
S6 Nonsynonymous SNV 649 2.3 7579358 7579358 C A R110L 25
S7 Nonsynonymous SNV 1571 2.2 7578394 7578394 T C H179R 114
S7 Nonsynonymous SNV 1280 3.6 7578203 7578203 C A V216L 7
S7 Nonsynonymous SNV 1280 2.7 7578191 7578191 A G Y220H 12
S7 Nonsynonymous SNV 944 2.9 7577524 7577524 T G T253P 3
S12 Nonsynonymous SNV 197 2.0 7579362 7579362 A G F70L 2
S13 Nonsynonymous SNV 522 2.1 7579358 7579358 C G R110P 9
S14 Nonsynonymous SNV 967 5.5 7578190 7578190 T C Y220C 231
S15 Splicing 1055 2.2 7574035 7574035 T G 0
S15 Nonframeshift deletion 986 2.9 7577580 7577585 TAGTGG – 0
S15 Nonsynonymous SNV 987 3.7 7577530 7577530 T A I251F 8
S15 Nonsynonymous SNV 989 2.2 7577547 7577547 C T G254D 110
S16 Nonsynonymous SNV 1445 13.2 7578522 7578522 T A Q136H 1
S16 Nonsynonymous SNV 880 2.6 7578396 7578396 G T H178Q 4
S16 Nonsynonymous SNV 646 2.8 7577139 7577139 G A R267W 26
S22 Nonsynonymous SNV 869 2.2 7577539 7577539 G A R248W 495
S23 Nonsynonymous SNV 810 2.5 7577139 7577139 G A R267W 26
S24 Nonsynonymous SNV 345 2.6 7579358 7579358 C A R71L 25
S25 Frameshift deletion 1844 3.0 7579879 7579879 G – 0
S26 Nonsynonymous SNV 936 4.1 7578260 7578260 C T V197M 10
S26 Stopgain SNV 825 3.5 7574003 7574003 G A R342* 74
S27 Splicing 950 9.8 7577610 7577610 T A 10
S28 Nonsynonymous SNV 485 2.5 7578448 7578448 G T A29D 9
S28 Nonsynonymous SNV 800 2.9 7578190 7578190 T C Y220 231
S28 Stopgain SNV 372 5.1 7577100 7577100 T A R148X 10
S29 Nonsynonymous SNV 1504 2.3 7578266 7578266 T A I195F 21
S29 Nonsynonymous SNV 748 3.6 7578235 7578235 T C Y205C 66
S29 Nonsynonymous SNV 877 6.6 7577565 7577565 T C N239S 21
S29 Nonsynonymous SNV 879 4.9 7577539 7577539 G A R248W 495
S30 Nonsynonymous SNV 356 11.2 7577121 7577121 G A R141C 474
S30 Stopgain SNV 1091 5.7 7574021 7574021 C A E336* 4
S31 Nonsynonymous SNV 1225 5.7 7578526 7578526 C T C135Y 52
S31 Frameshift deletion 694 3.7 7577599 7577599 C – 0
S31 Nonsynonymous SNV 702 5.0 7577536 7577536 T A R249W 34
S31 Nonsynonymous SNV 502 2.4 7577124 7577124 C A V272L 23
S32 Nonsynonymous SNV 1079 2.5 7577559 7577559 G A S241F 73
S32 Nonsynonymous SNV 1080 4.8 7577570 7577570 C T M237I 68
S32 Nonsynonymous SNV 537 4.8 7577098 7577098 T A R280S 11
S32 Nonsynonymous SNV 538 3.0 7577094 7577094 G A R282W 395
S32 Nonsynonymous SNV 1638 2.6 7578538 7578538 T C N131S 4
S33 Splicing 1416 4.5 7578370 7578370 C T 21
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Sample ID Mutation type Coverage Frequency Start position End position Reference allele Mutated allele Amino acid change Cosmic occurrence
S33 Nonsynonymous SNV 1393 4.5 7578406 7578406 C T R175H 818
S33 Nonsynonymous SNV 339 5.0 7577124 7577124 C A V140L 23
S33 Stopgain SNV 339 6.8 7577058 7577058 C A E162X 43
S34 Nonsynonymous SNV 1394 13.8 7578190 7578190 T C Y220C 231
S34 Nonsynonymous SNV 1346 9.2 7578536 7578536 T G K132Q 10
S35 Nonsynonymous SNV 679 23.4 7577559 7577559 G A S241F 73
S36 Nonsynonymous SNV 2181 2.5 7578395 7578395 G A H179Y 85
S36 Nonsynonymous SNV 2181 4.4 7578393 7578393 A T H179Q 12
S36 Nonsynonymous SNV 1147 4.3 7578271 7578271 T C H193R 81
S36 Nonsynonymous SNV 674 9.5 7577538 7577538 C T R248Q 565
S36 Nonsynonymous SNV 563 2.7 7577121 7577121 G A R273C 474
S36 Frameshift deletion 583 2.2 7579391 7579391 G – 0
S37 Nonsynonymous SNV 717 4.0 7578454 7578454 G A A159V 37
S37 Nonsynonymous SNV 691 8.7 7577547 7577547 C A G245V 62
S37 Nonsynonymous SNV 607 14.5 7577120 7577120 C T R273H 513
S37 Nonsynonymous SNV 645 3.7 7579358 7579358 C A R110L 25
S38 Splicing 896 6.5 7577609 7577609 C T 13
S38 Frameshift insertion 899 6.3 7577530 7577530 – T I119fs 0
S38 Nonsynonymous SNV 899 2.6 7577528 7577528 G C I251M 0
S38 Nonsynonymous SNV 454 26.7 7577098 7577098 T G R148S 5
NOTE. The asterisks indicate the termination of translation.
SNV, single nucleotide variant.
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